Abstract：Objective To investigate the effect of Gemcitabine combined with Erlotinib in the treatment of advanced pancreatic cancer.Methods Forty patients with advanced pancreatic cancer admitted to our hospital from January 2017 to January 2018 were selected as the research objects for retrospective analysis.They were divided into control group(20 cases) and observation group (20 cases) according to different treatment methods.Patients in the observation group were treated with Gemcitabine combined with Erlotinib,while patients in the control group were treated with Gemcitabine combined with Tegafur.The clinical therapeutic effects,clinical benefits (pain relief intensity ≥50%,analgesic drug dosage reduction ≥50%,weight gain >7%) and adverse reactions (leukopenia,thrombocytopenia,rash,nausea and vomiting,transaminase elevation) were compared between the two groups.Results The total effective rate of patients in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).The total clinical benefit rate of patients in the observation group was higher than that in the control group,and the difference was statistically significant (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion After Gemcitabine combined with Erlotinib is adopted for advanced pancreatic cancer patients,the total treatment efficiency and clinical total benefit rate of the patients are improved,the incidence rate of adverse reactions of the patients is not increased,and the method has higher clinical application value.
王敏; 赵建华. 吉西他滨联合厄洛替尼治疗晚期胰腺癌的效果[J]. 中国当代医药, 2020, 27(2): 81-83.
WANG Min; ZHAO Jian-hua. Effect of Gemcitabine combined with Erlotinib in the treatment of advanced pancreatic cancer. 中国当代医药, 2020, 27(2): 81-83.
京公网安备 11010502046607号